Tethered agonist analogs as site-specific probes for domains of the human α7 nicotinic acetylcholine receptor that differentially regulate activation and desensitization.
Homomeric α7 nicotinic acetylcholine receptors represent an important and complex pharmaceutical target. They can be activated by structurally diverse agonists and are highly likely to enter and remain in desensitized states at rates determined by the structures of the agonists. To identify structural elements regulating this function, we introduced reactive cysteines into the α7 ligand-binding domain allowing us to bind sulfhydryl-reactive (SH) agonist analogs or control reagents onto specific positions in the ligand binding domain. We identified four α7 mutants (S36C, L38C, W55C, and L119C) in which the tethering of the SH reagents blocked further acetylcholine-evoked activation of the receptor. However, after selective reaction with SH agonist analogs, the type II allosteric modulator N-(5-chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl-3-isoxazolyl)-urea (PNU-120596) could reactivate L119C and W55C mutants and receptors with a reduced or modified C-loop. Modified S36C and L38C mutants were insensitive to reactivation by PNU-120596, whether they were reacted with agonist analogs or alternative SH reagents. Molecular modeling showed that in the W55C and L119C mutants, the ammonium pharmacophore of the agonist analog methanethiosulfonate-ethyltrimethylammonium would be in a similar but nonidentical position underneath the C-loop. The orientation assumed by the ligand tethered to 119C was approximately 3-fold more sensitive to PNU-120596 than the alternative pose at 55C. Our results support the hypothesis that a single ligand can bind within the receptor in different ways and, depending on the specific binding pose, may variously promote activation or desensitization, or, alternatively, function as a competitive antagonist. This insight may provide a new approach for drug development.
Wang
Jingyi
J
Department of Pharmacology and Therapeutics University of Florida, Gainesville, FL 32610-0267, USA.
Horenstein
Nicole A
NA
Stokes
Clare
C
Papke
Roger L
RL
D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites / Q000502:physiology; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000378:metabolism* / Q000494:pharmacology; D015335:Molecular Probes / Q000737:chemistry* / Q000502:physiology*; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics; D018722:Nicotinic Agonists / Q000378:metabolism* / Q000494:pharmacology; D009865:Oocytes; D010671:Phenylurea Compounds / Q000378:metabolism* / Q000494:pharmacology; D017434:Protein Structure, Tertiary / Q000502:physiology; D011978:Receptors, Nicotinic / Q000737:chemistry* / Q000378:metabolism / Q000502:physiology*; D014982:Xenopus laevis; D064569:alpha7 Nicotinic Acetylcholine Receptor
C508388:1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea; C579167:Chrna7 protein, human; D007555:Isoxazoles; D015335:Molecular Probes; D018722:Nicotinic Agonists; D010671:Phenylurea Compounds; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor
Neuron. 2004 Mar 25;41(6):907-14
15046723
Methods Enzymol. 1996;266:383-402
8743695
Mol Pharmacol. 2009 Aug;76(2):253-63
19411608
Biochemistry. 1986 Sep 23;25(19):5595-601
3778876
Nature. 2001 May 17;411(6835):269-76
11357122
Nature. 2003 Jun 26;423(6943):949-55
12827192
Methods Enzymol. 1998;293:123-45
9711606
Nature. 2003 Jan 23;421(6921):384-8
12508119
Mol Pharmacol. 2008 Dec;74(6):1496-511
18768388
Eur J Pharmacol. 2000 Mar 30;393(1-3):179-95
10771012
Biochemistry. 2006 Sep 5;45(35):10641-53
16939216
AAPS J. 2006 Jan 13;7(4):E885-94
16594641
Biochem Pharmacol. 2007 Oct 15;74(8):1102-11
17597586
Mol Pharmacol. 2007 Sep;72(3):715-24
17565004
Neuroreport. 1999 Nov 26;10(17):3485-9
10619630
Br J Pharmacol. 2007 Aug;151(7):915-29
17502850
J Mol Biol. 2002 Jun 21;319(5):1165-76
12079355
Shock. 2007 Dec;28(6):700-3
17621262
Neuropsychopharmacology. 2004 May;29(5):891-900
14970827
Neuropharmacology. 2009 Jan;56(1):237-46
18723036
Neuropharmacology. 2011 Jan;60(1):159-71
20650284
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14686-91
18791069
Brain Res. 1999 Jun 5;830(2):218-25
10366678
Nature. 2001 May 17;411(6835):261-8
11357121
J Comp Neurol. 1986 Sep 15;251(3):407-13
3771837
Mol Pharmacol. 2002 Feb;61(2):463-72
11809872
Br J Pharmacol. 2002 Sep;137(1):49-61
12183330
Mol Pharmacol. 2008 Nov;74(5):1407-16
18678621
Biochemistry. 1999 Apr 20;38(16):4912-21
10213592
Annu Rev Biophys Biomol Struct. 2003;32:311-34
12695308
EMBO J. 2005 Oct 19;24(20):3635-46
16193063
J Pharmacol Exp Ther. 2009 May;329(2):791-807
19223664
Crit Care Med. 2007 Apr;35(4):1139-44
17334244